MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, CTXR made $1,667,298 in revenue. -$21,231,140 in net income. Net profit margin of -1273.39%.

Income Overview

Revenue
$1,667,298
Net Income
-$21,231,140
Net Profit Margin
-1273.39%
EPS
-$0.95
Unit: Dollar
Revenue Breakdown
    • Gross Product Revenue
    • Grosstonet Adjustments

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenues
1,667,298 3,944,111 -0
Cost of revenues
328,878 789,208 --
Gross profit
1,338,420 3,154,903 --
Research and development
1,633,518 1,599,719 1,641,586 1,621,325
Amortization of in-process research and development
1,720,312 573,438 --
General and administrative
26,391,101 5,720,727 3,905,961 4,447,008
Stock-based compensation general and administrative
3,788,275 4,280,227 2,889,762 2,719,674
Total operating expenses
33,533,206 12,174,111 8,437,309 8,788,007
Operating loss
-32,194,786 -9,019,208 -8,437,309 -8,788,007
Interest income
53,584 45,097 53,423 20,637
Gain on sale of new jersey net operating losses
3,833,277 ---
Interest expense
33,031 155,538 95,520 172,262
Gain on sale of new jersey net operating losses
---0
Total other income, net
3,853,830 -110,441 -42,097 -151,625
Loss before income taxes
-28,340,956 -9,129,649 -8,479,406 -8,939,632
Income tax expense (benefit)
-231,210 264,240 264,240 264,240
Net loss
-28,109,746 -9,393,889 -8,743,646 -9,203,872
Net loss attributable to non-controlling interest
-6,878,606 -1,173,104 -784,358 -414,000
Deemed dividend on warrant extension
---0
Net loss applicable to common stockholders
-21,231,140 -8,220,785 -7,959,288 -8,789,872
Basic EPS
-0.95 -0.38 -0.463 -0.8
Diluted EPS
-0.95 -0.38 -0.463 -0.8
Basic Average Shares
22,376,427 21,495,274 17,180,337 11,006,896
Diluted Average Shares
22,376,427 21,495,274 17,180,337 11,006,896
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss applicableto common...-$21,231,140 (-94.49%↓ Y/Y)Net lossattributable to...-$6,878,606 (-1056.07%↓ Y/Y)Net loss-$28,109,746 (-144.19%↓ Y/Y)Income tax expense(benefit)-$231,210 (-187.50%↓ Y/Y)Gain on sale of newjersey net operating...$3,833,277 Interest income$53,584 (299.49%↑ Y/Y)Gross Product Revenue$2,003,760 Loss before incometaxes-$28,340,956 (-151.98%↓ Y/Y)Total other income,net$3,853,830 (28632.05%↑ Y/Y)Revenues$1,667,298 Interest expense$33,031 Grosstonet Adjustments$336,462 Operating loss-$32,194,786 (-185.90%↓ Y/Y)Gross profit$1,338,420 Cost of revenues$328,878 Total operatingexpenses$33,533,206 (197.79%↑ Y/Y)General andadministrative$26,391,101 (450.72%↑ Y/Y)Stock-based compensation general and...$3,788,275 (40.20%↑ Y/Y)Amortization of in-processresearch and development$1,720,312 Research and development$1,633,518 (-56.63%↓ Y/Y)

Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals, Inc. (CTXR)